Application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of drug for prevention and treatment of thromboembolic diseases

A depolymerized holothurian glycosaminoglycan (DHG) that is used for the preparation of a drug for prevention or treatment peripheral vascular thrombosis obliterans diseases, wherein the drug comprises depolymerized holothurian glycosaminoglycan and a pharmaceutically acceptable carrier, in which the depolymerized holothurian glycosaminoglycan has a weight-average molecular weights between 26,000 Da and 45,000 Da;

• wherein the depolymerized holothurian glycosaminoglycan is prepared via a process that comprises the steps as follows:
• (1) mincing a holothurian, wherein the holothurian is Holothuria leucospilota,
• (2) adding an enzyme into the minced holothurian, wherein the enzyme comprises a proteolytic enzyme and a compound pancreatin, an amount of the proteolytic enzyme is 2% of a weight of the holothurian, and an amount of the compound pancreatin is 2% of the weight of the holothurian;
• (3) performing an enzymatic hydrolysis and precipitation on the product of step (2) to form a holothurian glycosaminoglycan,
• (4) collecting a crude product of holothurian glycosaminoglycan,
• (5) purifying and decolorizing the crude product of holothurian glycosaminoglycan, and
• (6) collecting the holothurian glycosaminoglycan;
• (7) adding hydrogen peroxide with a weight concentration of about 5% to about 10% into a product obtained in the step (6) for degradation,
• (8) collecting a depolymerized holothurian glycosaminoglycan with a weight average molecular weight within a range of from 26,000 Da to 45,000 Da.

A depolymerized holothurian glycosaminoglycan (DHG) that is used for the preparation of a drug for prevention or treatment, wherein the drug comprises depolymerized holothurian glycosaminoglycan and a pharmaceutically acceptable carrier, in which the depolymerized holothurian glycosaminoglycan has a weight-average molecular weights between 26,000 Da and 45,000 Da;

• wherein the depolymerized holothurian glycosaminoglycan is prepared via a process that comprises the steps as follows:
• (1) mincing a holothurian, wherein the holothurian is Holothuria leucospilota,
• (2) adding an enzyme into the minced holothurian, wherein the enzyme comprises a proteolytic enzyme and a compound pancreatin, an amount of the proteolytic enzyme is 2% of a weight of the holothurian, and an amount of the compound pancreatin is 2% of the weight of the holothurian;
• (3) performing an enzymatic hydrolysis and precipitation on the product of step (2) to form a holothurian glycosaminoglycan,
• (4) collecting a crude product of holothurian glycosaminoglycan,
• (5) purifying and decolorizing the crude product of holothurian glycosaminoglycan, and
• (6) collecting the holothurian glycosaminoglycan;
• (7) adding hydrogen peroxide with a weight concentration of about 5% to about 10% into a product obtained in the step (6) for degradation,
• (8) collecting a depolymerized holothurian glycosaminoglycan with a weight average molecular weight within a range of from 26,000 Da to 45,000 Da.

A depolymerized holothurian glycosaminoglycan (DHG) that is used for the preparation of a drug for prevention or treatment of cardiovascular diseases or peripheral vascular thrombosis obliterans diseases, which is characterized in that the drug comprises more than one of depolymerized holothurian glycosaminoglycans with weight-average molecular weights between 26,000 Da and 45,000 Da and a pharmaceutically acceptable carrier;

• (1) mincing a holothurian, wherein the holothurian is Holothuria leucospilota,
• (2) adding an enzyme into the minced holothurian, wherein the enzyme comprises a proteolytic enzyme and a compound pancreatin, an amount of the proteolytic enzyme is 2% of a weight of the holothurian, and an amount of the compound pancreatin is 2% of the weight of the holothurian;
• (3) performing an enzymatic hydrolysis and precipitation on the product of step (2) to form a holothurian glycosaminoglycan,
• (4) collecting a crude product of holothurian glycosaminoglycan,
• (5) purifying and decolorizing the crude product of holothurian glycosaminoglycan, and
• (6) collecting the holothurian glycosaminoglycan;
• (7) adding hydrogen peroxide with a weight concentration of about 5% to about 10% into a product obtained in the step (6) for degradation,
• (8) collecting a depolymerized holothurian glycosaminoglycan with a weight average molecular weight within a range of from 26,000 Da to 45,000 Da.

A depolymerized holothurian glycosaminoglycan (DHG) that is used for the preparation of a drug for prevention or treatment of postoperative thrombotic diseases, which is characterized in that the drug comprises more than one of depolymerized holothurian glycosaminoglycan with weight-average molecular weights between 26,000 Da and 45,000 Da and a pharmaceutically acceptable carrier;

• (1) mincing a holothurian, wherein the holothurian is Holothuria leucospilota,
• (2) adding an enzyme into the minced holothurian, wherein the enzyme comprises a proteolytic enzyme and a compound pancreatin, an amount of the proteolytic enzyme is 2% of a weight of the holothurian, and an amount of the compound pancreatin is 2% of the weight of the holothurian;
• (3) performing an enzymatic hydrolysis and precipitation on the product of step (2) to form a holothurian glycosaminoglycan,
• (4) collecting a crude product of holothurian glycosaminoglycan,
• (5) purifying and decolorizing the crude product of holothurian glycosaminoglycan, and
• (6) collecting the holothurian glycosaminoglycan;
• (7) adding hydrogen peroxide with a weight concentration of about 5% to about 10% into a product obtained in the step (6) for degradation,
• (8) collecting a depolymerized holothurian glycosaminoglycan with a weight average molecular weight within a range of from 26,000 Da to 45,000 Da.